Zydus Lifesciences Receives USFDA Final Approval for Ammonium Lactate Cream

Strategic & Commercial Highlights Market Opportunity: According to IQVIA MAT December 2025 data, Ammonium Lactate Cream recorded annual sales of approximately $15 million in the United States. Therapeutic Indication: The product is a prescription-strength alpha-hydroxy acid indicated for the treatment of xerosis (dry, scaly skin) and ichthyosis vulgaris (an inherited skin condition). Manufacturing & Logistics: The cream will be produced at the group’s dedicated topical manufacturing facility in Changodar, Ahmedabad. Distribution in the U.S. will be managed by Viona Pharmaceuticals Inc. Regulatory Strength and Portfolio Growth This milestone underscores Zydus' robust regulatory pipeline and consistent compliance standards: Approval Milestone: The group now holds a total of 430 USFDA approvals. Pipeline Velocity: Zydus has filed over 505 Abbreviated New Drug Applications (ANDAs) since the inception of its filing process in FY 2003-04. Facility Track Record: The Changodar topical site has a history of successful USFDA inspections, maintaining the high-quality standards required for complex formulation exports. Investor Context & Market Position Following the announcement, Zydus Lifesciences' shares closed at ₹906.50, reflecting a gain of 1.57%. The approval aligns with the company's broader strategy to diversify its U.S. portfolio beyond oral solids into high-value dermatology and topical treatments. Note to Investors: This approval follows a strong Q3 performance where Zydus saw revenue growth driven by its U.S. formulations business, which currently contributes nearly half of the total consolidated revenue.